MetaADEDB 2.0 @ LMMD
Histrelin acetate
(BKEMVGVBBDMHKL-VYFXDUNUSA-N)
Structure
SMILES
CC(=O)O.CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](Cc1ncn(c1)Cc1ccccc1)NC(=O)[C@H](Cc1ccc(cc1)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)CO)CC(C)C)CCCN=C(N)N
Type(s)
Approved
ATC code(s)
L02AE05
Molecular Formula:
C70H94N18O16
Molecular Weight:
1443.610
Log P:
3.9796
Hydrogen Bond Acceptor:
32
Hydrogen Bond Donor:
17
TPSA:
523.96
CAS Number(s):
76712-82-8
Synonym(s)
1.
Histrelin acetate
External Link(s)
PubChem Compound56927879
ChEBI63530
CHEMBLCHEMBL1201255
DrugBankDB06788
KEGGdr:D02369
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Device breakageFAERS: 11US FAERS
2Procedural complicationFAERS: 10US FAERS
3Drug ineffectiveFAERS: 6US FAERS
4Incorrect drug administration durationFAERS: 6US FAERS
5FatigueFAERS: 5US FAERS
6Complication of device removalFAERS: 3US FAERS
7Device extrusionFAERS: 3US FAERS
8Cerebrovascular accidentFAERS: 2US FAERS
9ChillsFAERS: 2US FAERS
10Device expulsionFAERS: 2US FAERS
11Drug administered to patient of inappropriate ageFAERS: 2US FAERS
12Implant site infectionFAERS: 2US FAERS
13Implant site inflammationFAERS: 2US FAERS
14Implant site swellingFAERS: 2US FAERS
15Joint swellingFAERS: 2US FAERS
16AbscessFAERS: 1US FAERS
17AnxietyFAERS: 1US FAERS
18ArthralgiaFAERS: 1US FAERS
19AstheniaFAERS: 1US FAERS
20Back PainFAERS: 1US FAERS
21Blood testosterone decreasedFAERS: 1US FAERS
22Blood testosterone increasedFAERS: 1US FAERS
23CellulitisFAERS: 1US FAERS
24DermatitisFAERS: 1US FAERS
25Diabetes mellitus inadequate controlFAERS: 1US FAERS
26Disease ProgressionFAERS: 1US FAERS
27DizzinessFAERS: 1US FAERS
28Drug ineffective for unapproved indicationFAERS: 1US FAERS
29Drug prescribing errorFAERS: 1US FAERS
30Erectile dysfunctionFAERS: 1US FAERS
31ErythemaFAERS: 1US FAERS
32Expulsion of medicationFAERS: 1US FAERS
33Feeling jitteryFAERS: 1US FAERS
34Feeling of body temperature changeFAERS: 1US FAERS
35HeadacheFAERS: 1US FAERS
36Implant site abscessFAERS: 1US FAERS
37Implant site cellulitisFAERS: 1US FAERS
38Implant site dischargeFAERS: 1US FAERS
39Implant site effusionFAERS: 1US FAERS
40Implant site erythemaFAERS: 1US FAERS
41Implant site fibrosisFAERS: 1US FAERS
42Implant site thrombosisFAERS: 1US FAERS
43Inappropriate schedule of product administrationFAERS: 1US FAERS
44Incorrect product administration durationFAERS: 1US FAERS
45Intentional product use issueFAERS: 1US FAERS
46MalaiseFAERS: 1US FAERS
47MastitisFAERS: 1US FAERS
48Mental status changesFAERS: 1US FAERS
49MetastasisFAERS: 1US FAERS
50Mood swingsFAERS: 1US FAERS
51NocturiaFAERS: 1US FAERS
52Product dispensing errorFAERS: 1US FAERS
53Product dose omissionFAERS: 1US FAERS
54PruritusFAERS: 1US FAERS
55Sexual DysfunctionFAERS: 1US FAERS
56SinusitisFAERS: 1US FAERS
57Skin irritationFAERS: 1US FAERS
58Skin reactionFAERS: 1US FAERS
59Urinary RetentionFAERS: 1US FAERS
60Urinary hesitationFAERS: 1US FAERS
61Wrong technique in drug usage processFAERS: 1US FAERS
62Wrong technique in product usage processFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.